|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
CN100447244C
(zh)
|
1999-08-17 |
2008-12-31 |
比奥根艾迪克Ma公司 |
Baff受体(bcma),一种免疫调节剂
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
WO2002066516A2
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
JP2005500061A
(ja)
|
2001-08-20 |
2005-01-06 |
ザ スクリップス リサーチ インスティテュート |
Ｃｎｎについての亜鉛フィンガー結合ドメイン
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
DE10328289B3
(de)
|
2003-06-23 |
2005-01-05 |
Enginion Ag |
Arbeitsmedium für Dampfkreisprozesse
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
WO2006044643A2
(en)
|
2004-10-15 |
2006-04-27 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
US7641903B2
(en)
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
US20120294863A1
(en)
|
2004-10-15 |
2012-11-22 |
Seattle Genetics, Inc. |
Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
|
|
WO2006060878A1
(en)
|
2004-12-10 |
2006-06-15 |
Peter Maccallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
JP5122441B2
(ja)
*
|
2005-04-19 |
2013-01-16 |
シアトル ジェネティックス， インコーポレイテッド |
ヒト化抗ｃｄ７０結合剤およびその使用
|
|
CN103145842A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
|
MX2009006277A
(es)
*
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
WO2009033095A2
(en)
|
2007-09-07 |
2009-03-12 |
Cisthera, Incorporated |
Humanized pai-1 antibodies
|
|
US9120854B2
(en)
|
2008-04-11 |
2015-09-01 |
Seattle Genetics, Inc. |
Detection and treatment of pancreatic, ovarian and other cancers
|
|
CA2729567C
(en)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
KR101773216B1
(ko)
|
2009-12-29 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ27 항체
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
MX2013004792A
(es)
|
2010-10-27 |
2013-08-27 |
Baylor College Medicine |
Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2686347B1
(en)
|
2011-03-16 |
2018-05-02 |
argenx BVBA |
Antibodies to cd70
|
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
TWI495644B
(zh)
|
2011-11-11 |
2015-08-11 |
Rinat Neuroscience Corp |
營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
KR20130060720A
(ko)
|
2011-11-30 |
2013-06-10 |
한국전자통신연구원 |
목적 기반 시맨틱 서비스 디스커버리를 위한 서비스 목적 해석 장치 및 방법
|
|
NZ629697A
(en)
|
2012-03-15 |
2017-01-27 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods and uses
|
|
RU2766608C2
(ru)
|
2012-04-11 |
2022-03-15 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
WO2014068079A1
(en)
|
2012-11-01 |
2014-05-08 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
WO2014158821A1
(en)
|
2013-03-12 |
2014-10-02 |
Imaginab, Inc. |
Antigen binding constructs to cd70
|
|
AU2014248640B2
(en)
|
2013-03-13 |
2018-03-01 |
Seagen Inc. |
Cyclodextrin and antibody-drug conjugate formulations
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
MX373687B
(es)
|
2013-11-21 |
2020-07-07 |
Ucl Business Ltd |
Célula natural (nk)
|
|
AU2015214145A1
(en)
|
2014-02-04 |
2016-08-25 |
Kite Pharma. Inc. |
Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
|
|
WO2015121454A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
EP3114217A4
(en)
|
2014-03-07 |
2017-09-20 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
JP6681837B2
(ja)
|
2014-03-11 |
2020-04-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
同種移植に適合するｔ細胞を作製するための方法
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
WO2015161276A2
(en)
*
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
CA2945388A1
(en)
|
2014-04-23 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) for use in therapy and methods for making the same
|
|
ES2836743T3
(es)
*
|
2014-06-02 |
2021-06-28 |
Us Health |
Receptores de antígeno quiméricos que seleccionan como diana CD-19
|
|
WO2015188056A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
ES2878449T3
(es)
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
WO2016016341A1
(en)
|
2014-07-29 |
2016-02-04 |
Cellectis |
EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
|
|
US20180080008A1
(en)
|
2014-08-12 |
2018-03-22 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US20170335331A1
(en)
*
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
|
EP3215623A4
(en)
|
2014-11-06 |
2018-09-26 |
President and Fellows of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
EP3230310B1
(en)
*
|
2014-12-08 |
2019-06-12 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd70 chimeric antigen receptors
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
EP3233900A2
(en)
|
2014-12-19 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptors and methods of use thereof
|
|
BR112017013981A2
(pt)
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
AU2016243583B2
(en)
|
2015-03-27 |
2022-03-10 |
President And Fellows Of Harvard College |
Modified T cells and methods of making and using the same
|
|
KR102888521B1
(ko)
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
CN104910278B
(zh)
|
2015-05-27 |
2018-05-25 |
上海吉凯基因科技有限公司 |
一种用于制备cart细胞的具有高效转染能力和生物学活性的慢病毒
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
JP2018534264A
(ja)
|
2015-09-28 |
2018-11-22 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
|
|
JP6816133B2
(ja)
|
2015-10-05 |
2021-01-20 |
プレシジョン バイオサイエンシズ，インク． |
改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
|
|
GB201518136D0
(en)
|
2015-10-14 |
2015-11-25 |
Glaxosmithkline Ip Dev Ltd |
Novel chimeric antigen receptors
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
US10508143B1
(en)
|
2015-10-30 |
2019-12-17 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
CN108473575B
(zh)
|
2015-11-13 |
2022-04-19 |
美国卫生和人力服务部 |
抗-bcma多肽和蛋白质
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
BR112018012235A2
(pt)
|
2015-12-18 |
2018-12-04 |
Sangamo Therapeutics Inc |
rompimento alvejado do receptor de células de mhc
|
|
EP3389677B1
(en)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
|
CA3009637A1
(en)
|
2015-12-23 |
2017-06-29 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
ITUB20160112A1
(it)
|
2016-01-28 |
2016-04-28 |
Serteaweb Srl |
Processo di allarme e sistema televisivo relativo ad un tale processo di allarme
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
JP2019509738A
(ja)
|
2016-03-11 |
2019-04-11 |
ブルーバード バイオ， インコーポレイテッド |
ゲノム編集された免疫エフェクター細胞
|
|
EP3988111A1
(en)
|
2016-04-01 |
2022-04-27 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
US20190161530A1
(en)
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
EP3443002A4
(en)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
|
|
WO2017182608A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
|
US11141471B2
(en)
|
2016-04-25 |
2021-10-12 |
Regen BioPharma, Inc. |
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
|
US20190136230A1
(en)
|
2016-05-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
SG10202012157QA
(en)
|
2016-06-07 |
2021-01-28 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
CN106544321B
(zh)
|
2016-10-13 |
2019-01-29 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018068257A1
(zh)
|
2016-10-13 |
2018-04-19 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
WO2018132479A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
MX2019013514A
(es)
*
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
WO2019119036A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Benitec Biopharma Limited |
Cd70 deficient cells, and methods and reagents for producing same
|
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
US11957695B2
(en)
*
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|